Patient Considerations of Social Media Account Management After Death
Social Media Use in Advanced Cancer: Patient Considerations of Social Media Account Management After Death
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Identify the proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account (e.g. Facebook, Twitter, Instagram) management after death.
SECONDARY OBJECTIVE:
I. Identify the proportion of social media participation among advanced cancer patients seen in the supportive care clinic.
II. Evaluate the baseline awareness advanced cancer patients seen in the supportive care clinic have regarding how their Facebook account may be managed after death.
III. Evaluate affect changes and distress as a result from the conversation regarding their social media account management after death.
IV. Evaluate if discussion of social media account management among patients with advanced cancer in the supportive cancer clinic will increase their awareness of and motivation to address their social media account management options.
OUTLINE:
Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with at least 1 follow-up visit to the outpatient Supportive Care Clinic at MDACC
- Patients with any type of advanced cancer
- Patients aged 18 years or older
- Patients who have used social media
- Patients able to read and write in English
Exclusion Criteria:
- Delirium as diagnosed by treating Supportive Care Center (SCC) physician or Memorial Delirium Assessment Scale (MDAS) score >= 7
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observational (questionnaires)
Patients complete questionnaires over 30 minutes about level of anxiety and social media use and management.
|
Complete questionnaires
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients with advanced cancer in the supportive cancer clinic who have had discussions regarding their social media account
Time Frame: through study completion, an average of 1 year
|
Will be measured by Question 10 in the survey: "I have had conversations with my family or friends regarding how I would like any of my social media accounts managed after death", which contains five options: Strongly Disagree, Disagree, Neither Agree or Disagree, Agree, or Strongly Agree.
The results will be dichotomized into either "Strongly Agree/Agree" or "Neither Agree or Disagree/ Disagree/Strongly Disagree".
A two-sided 95% confidence interval will extend a maximum of 0.063 from the proportion of main interest.
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jacqueline M Tschanz, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-1171 (Other Identifier: M D Anderson Cancer Center)
- NCI-2021-04176 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Solid Neoplasm
-
NCT04697524CompletedIntegrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced CancerAdvanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
-
NCT03831295CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm
-
NCT04800627TerminatedLocally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
-
NCT03537690Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm
-
NCT03253679CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm
-
NCT05715281Active, not recruitingAdvanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm
-
NCT02317874CompletedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
-
NCT02070549CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid Neoplasm
-
NCT04729725TerminatedAdvanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
-
NCT05038839CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm
Clinical Trials on Questionnaire Administration
-
NCT04285957Completed
-
NCT02565433Terminated
-
NCT04179227Terminated
-
NCT05704335RecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head Pain
-
NCT04169542RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast Carcinoma
-
NCT04090619Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent Leukemia
-
NCT07199647CompletedMusculoskeletal Diseases | Chronic Pain
-
NCT05940974Active, not recruitingShoulder Arthropathy